Revergam 200 Mg/2 Ml & 500 Mg/2 Ml 200 mg & 500 mg Solution for Injection
PDF Leaflet Revision Date: 05 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Routine and immediate reversal of neuromuscular blockade induced by rocuronium or vecuronium.
Dosage (summary)
4 mg/kg for routine reversal; 16 mg/kg for immediate reversal at 3 mins post rocuronium.
Onset of Action / Duration
Onset: 3 mins, Duration: Not specified.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Obese patients
- Paediatric patients
Pregnancy & Breastfeeding
Safety in pregnancy not established; excretion in breast milk expected.
Key Drug Interactions
- Toremifene
- Fusidic acid
- Hormonal contraceptives
Contraindications
- Hypersensitivity to sugammadex
Common side effects
- Dysgeusia
- Cough
- Prolonged neuromuscular blockade
Counselling Points
- Monitor for signs of hypersensitivity.
- Ventilatory support may be required post-administration.
- Avoid re-administration of neuromuscular blockers too soon.
Serious warnings
- Marked bradycardia
- Risk of recurrence of neuromuscular blockade
- Not for use with depolarising neuromuscular blockers
Important Disclaimer
The Revergam 200 Mg/2 Ml & 500 Mg/2 Ml 200 mg & 500 mg Solution for Injection professional information leaflet below is the property of Lebasi Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
